A maker of pharma manufacturing workstations says wearable biometric ID products are solving a security and efficiency challenge. Traditionally, pharmaceutical manufacturers have used a complex patchwork of access points, workstations, and tools, according to Fremont, California–based Arista Corp. Think badges, passwords and more, with the potential for someone other than the intended operator to gain…
Otsuka partners with ICU Medical to enter U.S. IV products market
Otsuka Holdings will pay ICU Medical (Nasdaq: ICUI) an upfront payment of $200 million as part of a joint venture to enter the U.S. IV products market, which has been facing hurricane-related shortages this fall. The partnership — which involves ICU Medical providing commercial services for Otsuka’s Otsuka Pharmaceutical Factory (OPF) subsidiary — also includes…
Baxter exits China IV products market, focuses on U.S. shortages
Baxter recently stopped selling IV products in China as it continues its efforts to address hurricane-related supply shortages in the U.S. In a statement shared with Pharmaceutical Processing World, the Deerfield, Illinois–based company said: “After careful consideration, and given the numerous alternative IV solution suppliers that exist in the Chinese market, Baxter has suspended commercial…
Lilly expands manufacturing footprint in Ireland
Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…
Emergent presents its smallpox vaccine as a shield against mpox in Africa
Emergent BioSolutions says it will donate 50,000 doses of its ACAM2000 smallpox vaccine to help against the mpox outbreak in Africa. According to Emergent, the FDA is presently reviewing a supplemental Biologics License Application (sBLA) to expand ACAM2000’s indication to include mpox immunization. The company expects the FDA to complete its review in the third…
Pfizer opens expanded APIs plant in Singapore
Pfizer recently opened an extension of its highly automated active pharmaceutical ingredient (API) manufacturing facility in Tuas Biomedical Park in Singapore. The 429,000 ft2 expansion cost SGD $1 billion (U.S. $745 million), according to a July 23 news release from the Singapore Economic Development Board. Pfizer has passed final performance qualification checks at the facility…
Sanofi will build a new insulin plant in Germany
Sanofi recently announced that it will spend €1.3 billion ($1.4 billion) over the next five years to build a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany. The 36,000 m2 (equivalent to nearly 388,000 ft2) facility will replace existing insulin production plants. Paris-based Sanofi says several hundred highly qualified specialists will work…
Sanofi, Novartis among Time’s most sustainable companies
Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…
Veranova to spend $30M on Massachusetts facility
Veranova recently announced that it will invest $30 million in its Devens, Massachusetts facility to expand its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities The Wayne, Pennsylvania–based company — a specialist in making active pharmaceutical ingredients — said the investment in the Devens plant will build upon the site’s existing development…
Sanofi opens vaccine plant in Canada
French pharma giant Sanofi recently opened a pediatric and adult vaccine manufacturing facility on its Toronto campus. The facility officially opened on May 30. According to Sanofi, the new plant significantly increases its capacity to meet growing demand in Canada and around the world for pediatric and adult vaccines for pertussis (whooping cough), diphtheria and…